Jose Royo, Andalusian Center for Development Biology, Spain
Determining the role of genetic variations in the development of human diseases and using this information to develop better drug targets
Royo's group, then at Spanish biotech start-up Neocodex, had no SNP genotyping platform, so sequencing was affordable on the low scale, and he generally ran 5-15 SNPs in 1,000-2,000 samples. However, when medium-throughput projects arose, Royo's group faced the problem of genotyping 50-200 SNPs in 500 samples. "The investment in labeled oligos increased significantly the cost per sample," Royo writes in an E-mail, because they were faced with designing a different labeled primer for each SNP, the label being the most costly.
Royo's group developed a "universal" labeled primer whose complementary sequence was incorporated as...